Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Revolution MedicinesRVMD -0.93%25 3-1 Month Momentum % is 28.25% as of Aug. 13, 2026. GuruFocus rates RVMD with a GF Score™ of 25/100. The stock has 3 warning signs investors should review. Among 1,389 Biotechnology companies, Revolution Medicines ranks better than 89.2% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-13), Revolution Medicines's 3-1 Month Momentum % is 28.25%.
The industry rank for Revolution Medicines's 3-1 Month Momentum % or its related term are showing as below:
RVMD's 3-1 Month Momentum % is ranked better than 89.2% of 1389
companies
in the Biotechnology industry
Industry Median: -6.37
vs RVMD: 28.25
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Revolution Medicines 3-1 Month Momentum % Related Terms
RVMD vs ALNY, ONC, RPRX: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Revolution Medicines's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revolution Medicines 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Revolution Medicines's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Revolution Medicines's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revolution Medicines (RVMD) has a 3-1 Month Momentum % of 28.25% as of Aug. 13, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Revolution Medicines and its competitors. According to the industry distribution chart, Revolution Medicines ranks #150 out of 1389 companies in the Biotechnology industry, placing it in the top 10.8%.
Is Revolution Medicines' 3-1 Month Momentum % too high?
Revolution Medicines' current 3-1 Month Momentum % is 28.25%. Based on the distribution chart, Revolution Medicines ranks #150 out of 1389 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Revolution Medicines has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Revolution Medicines' 3-1 Month Momentum % compare to ALNY and ONC?
According to the Biotechnology industry distribution chart, Revolution Medicines ranks #150 out of 1389 companies for 3-1 Month Momentum %. This places Revolution Medicines in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Revolution Medicines and its competitors. Revolution Medicines's current 3-1 Month Momentum % is 28.25%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revolution Medicines stock overvalued right now?
Revolution Medicines (RVMD) has a current 3-1 Month Momentum % of 28.25%. The current 3-1 Month Momentum % is 28.25%. Revolution Medicines' overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Revolution Medicines (RVMD), the current 3-1 Month Momentum % is 28.25% as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
25GF Score
Get the complete analysis for RVMD
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RVMD has been successfully added to your 
